Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

RNA-seq analyses of JMJD3c-MYOD1-induced myogenic cells and human skeletal myotubes

ABSTRACT: We generated the human ES lines, in which the genome-wide reduction of H3K27me3 can be induced by the ectopic expression of catalytic domain of histone demethylase JMJD3 with doxycycline treatment (JMJD3c-hESCs). The overexpression of JMJD3c enhances MYOD1-mediated myogenic differentiation of hESCs. We compared the gene expression patterns of the generated myogenic cells with those of human skeletal myotubes.

ORGANISM(S): Homo sapiens

PROVIDER: GSE80106 | GEO | 2016/10/18

SECONDARY ACCESSION(S): PRJNA317930

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [ATAC-seq]

Project description:The study investigates how MyoD1 dosage controls myogenic cell fate, employing bulk RNA-seq, ATAC-seq, and CUT&RUN. We determined genome-wide transcriptional, chromatin accessibility, and MyoD1 binding profiles in C2C12 myoblasts expressing endogenous Halo-tagged MyoD1 or doxycycline-inducible Halo–MyoD1, under growth and differentiation conditions with low or high MyoD1 dosage.

2026-06-03 | GSE309864 | GEO

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [RNA-seq]

Project description:Transcription factor (TF) expression and dosage regulate developmental cell fate decisions. Increased TF dosage has been predicted to enhance expression of high-affinity target genes but also increase the binding of lower-affinity loci. The relative importance of high- versus lower-affinity TF binding in guiding cell fate decisions remains unclear. To test the roles of TF dosage, we examined the effects of increasing the dosage of MyoD1, the ?master regulator of myogenesis?, on skeletal muscle differentiation. Unexpectedly, increased MyoD1 dosage inhibited canonical myogenesis and redirected myoblast differentiation towards forming spontaneously contracting myotubes. This novel phenotype was driven by the MyoD1-dose-dependent upregulation of non-myogenic genes, including cell adhesion genes whose ectopic expression also inhibited classical myogenic differentiation and enabled myotube contraction. Live-cell single-molecule imaging showed that elevated MyoD1 dosage increased total chromatin binding and CUT&RUN profiling demonstrated that this increase occurred via preferential binding to lower-affinity loci. Integration of CUT&RUN, ATAC-seq and RNA-seq experiments revealed that increased MyoD1 binding correlated to the upregulation of otherwise unexpressed or lowly expressed genes. These findings suggest that increased MyoD1 dosage induced a selective gene regulatory expansion from high- to lower-affinity cis-regulatory elements, leading to activation of a broader ensemble of target genes, revealing a TF dose-dependent mechanism that can trigger distinct developmental programs. This submission contains additional RNA-seq samples generated that should be added to existing GEO Series GSE309864.

2026-06-03 | GSE309939 | GEO

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [CUT&Run]

Project description:Transcription factor (TF) expression and dosage regulate developmental cell fate decisions. Increased TF dosage has been predicted to enhance expression of high-affinity target genes but also increase the binding of lower-affinity loci. The relative importance of high- versus lower-affinity TF binding in guiding cell fate decisions remains unclear. To test the roles of TF dosage, we examined the effects of increasing the dosage of MyoD1, the “master regulator of myogenesis”, on skeletal muscle differentiation. Unexpectedly, increased MyoD1 dosage inhibited canonical myogenesis and redirected myoblast differentiation towards forming spontaneously contracting myotubes. This novel phenotype was driven by the MyoD1-dose-dependent upregulation of non-myogenic genes, including cell adhesion genes whose ectopic expression also inhibited classical myogenic differentiation and enabled myotube contraction. Live-cell single-molecule imaging showed that elevated MyoD1 dosage increased total chromatin binding and CUT&RUN profiling demonstrated that this increase occurred via preferential binding to lower-affinity loci. Integration of CUT&RUN, ATAC-seq and RNA-seq experiments revealed that increased MyoD1 binding correlated to the upregulation of otherwise unexpressed or lowly expressed genes. These findings suggest that increased MyoD1 dosage induced a selective gene regulatory expansion from high- to lower-affinity cis-regulatory elements, leading to activation of a broader ensemble of target genes, revealing a TF dose-dependent mechanism that can trigger distinct developmental programs.

2026-06-03 | GSE309919 | GEO

Molecular mechanisms implicated in myogenic differentiation of human alveolar mucosa derived cells

Project description:Different approaches of skeletal muscle cell regeneration originated from progenitor cells are extensively studied under the strategies of muscle tissue pathologies treatment. Recently it was discovered that anatomically localized alveolar mucosa multipotent mesenchymal stromal cells (AMC) are characterized by myogenic potential and high feasibility for muscle tissue recovery and regeneration. Although the resulting multinuclear myotubes are featured by expressing skeletal muscle specific markers (skeletal myosin, actin, myogenin and MyoD1) the exact molecular mechanism controlling differentiation of AMC in myogenic direction is still unclear and poorly scrutinized. In this research we used combination of large-scale transcriptome analysis and bioinformatics approach to appreciate molecular pathways and crucial nodes responsible for myogenic differentiation.

2019-07-13 | GSE134207 | GEO

ChIP-Seq data for histone marks in estrogen-inducible MyoD1 fibroblasts

Project description:The conversion of fibroblasts to myotubes by forced expression of MyoD1 is among the earliest demonstrations of reprogramming of vertebrate cell state. To gain insights into the chromatin state of genes required for reprogramming, we profiled H3K4me3, H3K27me3 and H3K9me3. DNA was enriched by chromatin immunoprecipitation (ChIP) and analyzed by Solexa sequencing. ChIP was performed using an antibody against H3K4me3, H3K27me3 and H3K9me3.

2010-07-24 | E-GEOD-23078 | biostudies-arrayexpress

RNA-seq analyses of JMJD3c-overexpressing human embryonic stem cells

Project description:We generated the human ES line, in which the genome-wide reduction of H3K27me3 can be induced by the ectopic expression of catalytic domain of histone demethylase JMJD3 with doxycycline treatment (JMJD3c-hESCs). The forced-demethylation of H3K27me3 triggered the upregulation of many developmental genes. Overexpression of JMJD3c mutant, which lacked catalytic activity, did not induce these changes. These results suggest that H3K27me3 demethylase activity of JMJD3 is necessary and sufficient for upregulation of developmental genes in hESCs.

2016-10-18 | GSE73583 | GEO

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [CUT&Run]

Project description:Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [CUT&Run]

| PRJNA1363998 | ENA

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [RNA-seq]

Project description:Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [RNA-seq]

| PRJNA1364018 | ENA

Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [ATAC-seq]

Project description:Modulating MyoD1 dosage activates alternate cell fate beyond myogenic differentiation [ATAC-seq]

| PRJNA1363908 | ENA

Transcriptional Heterogeneity of Progression in MYOD1-mutant spindle cell rhabdomyosarcoma

Project description:We perform single nuclei transcriptomics (snRNA-seq) analysis of patient-derived tumor samples to define the dynamic myogenic cell states and intratumoral transcriptional heterogeneity of MYOD1-mutant spindle cell/sclerosing rhabdomyosarcoma.

2026-01-22 | GSE288065 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data